Phosphodiesterase type III inhibitors are used for the treatment of severe heart failure and have two cardiovascular effects, reduction of vascular resistance, and increasing myocardial contractility to improve hemodynamic status. The combined therapy with dobutamine is more effective. It is recommended for acute or chronic heart failure with a β -blocker. We use them for the prevention of spasm of grafts, during coronary artery bypass grafting. For organ protection, phosphodiesterase type III inhibitors are also used for acute aortic dissection.

